With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Subscribe To Our Newsletter & Stay Updated